Anethole

Anethole

SCHEMBL57011

C/C=C\c1ccc(OC)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 1.00
CYP3A4 P08684 2/20 1.00
LMNA P02545 2/20 1.00
ALDH1A1 P00352 2/20 1.00
TP53 P04637 1/20 1.00
TSHR P16473 1/20 1.00
RELA Q04206 2/20 0.64
TRPA1 O75762 1/20 0.64
CYP1A2 P05177 3/20 0.61
CYP1A1 P04798 3/20 0.61
CYP1B1 Q16678 3/20 0.61
ESR1 P03372 2/20 0.61
PTGS2 P35354 2/20 0.61
TUBB4A P04350 2/20 0.61
TUBB P07437 2/20 0.61
TUBA3C P0DPH7 2/20 0.61
AHR P35869 2/20 0.61
TUBA1B P68363 2/20 0.61
TUBA4A P68366 2/20 0.61
TUBB4B P68371 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Anethole SCHEMBL48599 1.00 KDM4E (1.00) KDM4ECYP3A4LMNAALDH1A1TP53
Anethole SCHEMBL2222515 1.00 KDM4E (1.00) KDM4ECYP3A4LMNAALDH1A1TP53
Anethole SCHEMBL28973055 1.00 KDM4E (1.00) KDM4ECYP3A4LMNAALDH1A1TP53
Anethole SCHEMBL5309553 1.00 KDM4E (1.00) KDM4ECYP3A4LMNAALDH1A1TP53
Anethole SCHEMBL48600 1.00 KDM4E (1.00) KDM4ECYP3A4LMNAALDH1A1TP53
Anethole SCHEMBL2059918 0.98 KDM4E (0.95) KDM4ECYP3A4LMNAALDH1A1TP53
Anethole SCHEMBL2059915 0.98 KDM4E (0.95) KDM4ECYP3A4LMNAALDH1A1TP53
Anethole SCHEMBL28879104 0.98 KDM4E (0.95) KDM4ECYP3A4LMNAALDH1A1TP53
Anethole SCHEMBL29399255 0.98 KDM4E (0.95) KDM4ECYP3A4LMNAALDH1A1TP53
Anethole SCHEMBL28663138 0.98 KDM4E (0.95) KDM4ECYP3A4LMNAALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 496 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250113855-A1 HYDRATING AND REHYDRATING COMPOSITOIN AND PRODUCT IV THOUGHT PRODUCTS AND DESIGN CORP. 2025-04-10 US claimed
CN-115960516-B Polymer compound coating and preparation method thereof 浙江鱼童新材料股份有限公司 2023-09-19 CN claimed
CN-115960516-A Macromolecular compound coating and preparation method thereof 浙江鱼童新材料股份有限公司 2023-04-14 CN claimed
CN-114350328-B Modified nano alumina plugging agent and water-based drilling fluid 西南石油大学 2023-02-24 CN claimed
EP-3321319-B1 RESIN COMPOSITION AND PREPREG, RESIN SHEET, LAMINATE PLATE, AND PRINTED CIRCUIT BOARD MITSUBISHI GAS CHEMICAL CO (JP) 2022-10-05 EP claimed
CN-114350328-A Modified nano alumina plugging agent and water-based drilling fluid 西南石油大学 2022-04-15 CN claimed
US-20210355276-A1 Ketals and Polyketals as Release Agents THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2021-11-18 US claimed
WO-2020060908-A1 KETALS AND POLYKETALS AS RELEASE AGENTS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2020-03-26 WO claimed
US-10563029-B2 Resin composition and prepreg, resin sheet, laminate, and printed circuit board MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2020-02-18 US claimed
US-20190155975-A9 Antiperspirant and Deodorant Compositions Comprising Malodor Reduction Compositions THE PROCTER & GAMBLE COMPANY 2019-05-23 US claimed
US-6121234-A ORALLY COADMINISTERING TO MAMMAL PHARMACEUTICAL COMPOUND AND ESSENTIAL OIL AVMAX, INC. (US) 2000-09-19 US claimed
EP-0925320-A1 COATING COMPOSITIONS POLYMERISABLE AND/OR CROSS-LINKABLE BY ULTRAVIOLET OR VISIBLE LIGHT CRAY VALLEY SA (FR) 1999-06-30 EP claimed
EP-0831870-A4 USE OF ESSENTIAL OILS TO INCREASE BIOAVAILABILITY OF ORAL PHARMACEUTICAL COMPOUNDS AVMAX INC (US) 1998-09-16 EP claimed
EP-0252278-B1 Disinfecting agents and their use in disinfecting the skin and mucous membranes HENKEL KGAA (DE) 1998-08-19 EP claimed
EP-0831870-A1 USE OF ESSENTIAL OILS TO INCREASE BIOAVAILABILITY OF ORAL PHARMACEUTICAL COMPOUNDS Avmax, Inc. (US) 1998-04-01 EP claimed
WO-1998011152-A1 COATING COMPOSITIONS POLYMERISABLE AND/OR CROSS-LINKABLE BY ULTRAVIOLET OR VISIBLE LIGHT CRAY VALLEY S.A. (FR) 1998-03-19 WO claimed
US-5716928-A ADMINISTERING DRUG CONCURRENTLY WITH ESSENTIAL OIL AVMAX, INC. (US) 1998-02-10 US claimed
US-5665386-A Use of essential oils to increase bioavailability of oral pharmaceutical compounds AVMAX, INC. (US) 1997-09-09 US claimed
WO-1996040192-A1 USE OF ESSENTIAL OILS TO INCREASE BIOAVAILABILITY OF ORAL PHARMACEUTICAL COMPOUNDS AVMAX, INC. (US) 1996-12-19 WO claimed
US-4473713-A Hydrolysis of aryl-aliphatic ethers RHONE-POULENC SPECIALITES CHIMIQUES (FR) 1984-09-25 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210355276-A1 Ketals and Polyketals as Release Agents KARS1, KHK, KLKB1 KDM4E 626/4885CYP3A4 2600/4885LMNA 3150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.